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Background—The goal of this intravascular ultrasound investigation was to provide a more detailed morphological
analysis of the local biological effects of the implantation of a sirolimus-eluting stent compared with an uncoated stent.
Methods and Results—In the RAVEL trial, 238 patients with single de novo lesions were randomized to receive either an
18-mm sirolimus-eluting stent (Bx VELOCITY stent, Cordis) or an uncoated stent (Bx VELOCITY stent). In a subset
of 95 patients (sirolimus-eluting stent48, uncoated stent47), motorized intravascular ultrasound pullback (0.5 mm/s)
was performed at a 6-month follow-up. Stent volumes, total vessel volumes, and plaque-behind-stent volumes were
comparable. However, the difference in neointimal hyperplasia (25 versus 3728 mm3) and percent of volume
obstruction (13% versus 2920%) at 6 months between the 2 groups was highly significant (P0.001), emphasizing
the nearly complete abolition of the proliferative process inside the drug-eluting stent. Analysis of the proximal and
distal edge volumes showed no significant difference between the 2 groups in external elastic membrane or lumen and
plaque volume at the proximal and distal edges. There was also no evidence of intrastent thrombosis or persisting
dissection at the stent edges. Although there was a higher incidence of incomplete stent apposition in the sirolimus group
compared with the uncoated stent group (P0.05), it was not associated with any adverse clinical events at 1 year.
Conclusions—Sirolimus-eluting stents are effective in preventing neointimal hyperplasia without creating edge effect and
without affecting the plaque burden behind the struts. (Circulation. 2002;106:798-803.)
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The main limitation of the percutaneous techniques ofrevascularization remains the phenomenon of resteno-
sis, which is an exaggerated healing response to the vessel
wall injury that occurs as a result of mechanical dilatation.
The 3 processes involved in restenosis are immediate
elastic recoil, late constrictive remodeling, and neointimal
hyperplasia. The scaffolding properties of a stent can
control the first 2 processes but lead to an increase in
neointimal hyperplasia.
Pilot studies testing the safety, feasibility, and efficacy of
the sirolimus-eluting stent have demonstrated a near complete
abolition of neointimal hyperplasia.1,2 These pilot studies
have been conducted on patients with Benestent type lesions
in large vessels, and the stents were implanted under intra-
vascular ultrasound (IVUS) guidance.
The RAVEL trial is a multicenter randomized study involving
patients with more complex lesions in smaller vessels in whom
IVUS guidance was not used during stent implantation.3 In a subset
of the enrolled patients, quantitative 3-dimensional IVUS assess-
ment was performed at follow-up. The goal of this investigation was
to provide a more detailed morphological analysis of the local
biological effects of the implantation of a sirolimus-eluting stent.
Sirolimus has potent antiproliferative and antimigratory
effects.4 Intravascular brachytherapy also has antiprolif-
erative and antimigratory effects but has been associated
with certain side effects, including edge restenosis,5,6
persisting dissection,7,8 increased plaque burden outside
the struts of the stent with expansion of the external elastic
membrane,8,9 late malapposition,10 late thrombotic occlu-
sion,11 and “black holes.”12,13
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On the basis of the previous experience with brachyther-
apy, we specifically looked for any evidence of these harmful
effects in the patients enrolled in the RAVEL trial.
Methods
Patient Selection
The RAVEL trial enrolled 238 patients at 19 European and South
American medical centers, and a subset of 95 patients enrolled at 6
centers underwent an IVUS investigation of their stents at 6 months.
The study was reviewed and approved by each participating institu-
tion’s Ethics Review Committee. All randomized patients signed a
specific written informed consent mentioning the follow-up IVUS
investigation. Patients were eligible if they had a diagnosis of stable
or unstable angina pectoris or documented silent ischemia and if they
had a single de novo target lesion of a native coronary artery in a
vessel between 2.5 and 3.5 mm in diameter that could be covered by
an 18-mm stent. Patients were not eligible for enrollment if they had
an evolving myocardial infarction; an unprotected left main coronary
artery stenosis 50%; an ostial target lesion; a calcified lesion that
could not be successfully predilated; an angiographically visible
thrombus within the target lesion; a left ventricular ejection fraction
below 30%; or intolerance to aspirin, clopidogrel, or ticlopidine.
Study Procedures
After successful predilatation, patients were randomized 1:1 in a
double-blind fashion to undergo the implantation of either an
uncoated metal Bx VELOCITY Balloon-Expandable Stent or a
sirolimus-eluting Bx VELOCITY Balloon-Expandable Stent (Cordis
Corp, Johnson & Johnson). The sirolimus-eluting stents were indis-
tinguishable from the uncoated metal stents to the naked eye.
Postdilatation was performed as necessary to achieve a residual
stenosis below 20% with a TIMI grade III flow. In case of dissection
or of incomplete coverage of the lesion, additional study stents from
the same randomization assignment were used as necessary.
Heparin was administered in intravenous boluses to maintain an
activated clotting time 250 seconds for the duration of the procedure
and was discontinued within 12 hours. Aspirin, at least 100 mg, was
administered 12 hours before the procedure and continued indefinitely.
A loading dose of 300 mg of clopidogrel was administered, preferably
48 hours before the procedure, followed by 75 mg once daily for 8
weeks. Alternatively, ticlopidine 250 mg twice daily was begun 1 day
before the procedure and continued for 8 weeks.
Patient Follow-Up
At 30 days, 6 months, and 12 months, patients underwent evaluation
of anginal status according to the Canadian Cardiovascular Society
Classification of angina14 and the Braunwald Classification for
unstable angina,15 as well as monitoring of major adverse cardiac
events or additional revascularization of the index target lesion. A
12-lead ECG was performed at each visit; follow-up angiography
and an IVUS investigation was performed at 18030 days.
Quantitative Coronary Angiography
Coronary angiograms were obtained in multiple views after patients
had received an intracoronary injection of nitrates. Quantitative
analyses of all pre-, peri-, and postprocedural angiographic data were
performed by an independent core laboratory (Cardialysis, Rotter-
dam, the Netherlands) and analyzed quantitatively by edge-detection
techniques.16 These data have been reported previously.
Quantitative Intravascular Ultrasound
At a 6-month follow-up, stented vessel segments were examined
with mechanical IVUS (CardioVascular Imaging System, CVIS)
using automated pullback at 0.5 mm per second. A coronary segment
beginning 5 mm distal to and extending 5 mm proximal to the stented
segment was also examined. A computer-based contour detection
program was used for automated 3D reconstruction of the stented
segment from up to 200 cross-sectional images. Lumen, stent
boundaries, and external elastic membrane were detected using a
minimum cost algorithm.17,18 Total vessel volume (TVV), stent
volume (SV), and lumen volume (LV) were calculated as Vni1 Ai
· H, where V is volume, A is total vessel, stent, or lumen area (as
desired) in a given cross-sectional image, H is thickness of the
coronary artery slice, and n is the number of slices. Lumen volume
did not include the incomplete apposition spaces, and in absence of
neointimal hyperplasia, lumen volume was delineated by the bound-
aries of the struts. Total plaque volume (TPV), plaque volume behind
the stent (PBS), and neointimal hyperplasia (NIH) were calculated as
TVVLV, TVVSV, and SVLV, respectively. Percentage of
Figure 1. Methodology used to evaluate incomplete apposition at follow-up by IVUS. The figures illustrate the variety of measurements
performed to quantify the incomplete apposition observed: location of incomplete apposition (arrows a and b) on a longitudinal view
(A), circumferential extent in angular degree (B) maximal depth, distance between the vessel wall and the most incompletely apposed
strut (C), and the area of incomplete apposition (lumen areastent areaincomplete apposition area) in a single IVUS cross section (D).
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obstruction volume was calculated as neointimal volume/stent vol-
ume 100 at the 6-month follow-up. For the segments proximal and
distal to the stent, the vessel volume was measured at each cross
section as the area lying within the external elastic lamina.
Feasibility, reproducibility and inter- and intra-observer variability
of this system have been validated in vitro and in vivo.17,18 The
quantitative ultrasound analyses were performed by an independent
core laboratory (Cardialysis BV, Rotterdam, the Netherlands).
Qualitative IVUS parameters assessed in the study included
persisting edge tears and incomplete stent apposition. Edge tears
were defined as disruption of plaque immediately adjacent to the
stent ends, where the flap could be clearly differentiated from the
underlying plaque. Incomplete stent apposition was defined as 1 or
more struts clearly separated from vessel wall with evidence of blood
speckles behind the strut,19,20 and because it was based on the
consensus of 3 independent analysts, the determination was blind for
the type of stent used. The measures of agreement by Kappa analysis
between 3 observers were 0.87, 0.85 and 0.80, respectively (PNS).
The number of loci exhibiting areas of incomplete stent apposition
per stent was determined by cross-sectional IVUS images. The total
length of these single or multiple areas of incomplete apposition
were calculated from the number of frames involved. The maximal
number of struts separated from the vessel wall on 1 single cross
section, as well as the maximal depth (distance between the most
incompletely apposed strut and the vessel wall) and the maximal
circumferential extent of incomplete apposition (expressed in angu-
lar degrees) are reported. Finally, the volume of the incompletely
apposed segments was quantified in mm3 and related to the stent
volume-in percent (Figure 1).
End Points
The primary end point of the study is angiographic in-stent late loss at
a 6-month follow-up as determined by quantitative coronary angiogra-
phy. The secondary clinical end point of the study was a composite of
major adverse cardiac events, including cardiac and noncardiac death,
Q-wave and non–Q-wave myocardial infarctions, coronary artery by-
pass grafts, or target lesion or vessel revascularizations at 30 days, 6
months, and 12 months after the index procedure.3
Statistical Analysis
All analyses were performed on an intention-to-treat basis. Treat-
ment group differences were tested by ANOVA or Wilcoxon rank
sums scores for continuous variables. Discrete variables were de-
scribed by counts and percentages and tested with Fisher’s exact test.
The differences in event-free survival were compared by log-rank tests.
A 2-sided P value0.05 was considered statistically significant. To identify
potential causative factors responsible for incomplete apposition, a multi-
variate analysis was performed including all the conventional pre, peri-, and
postprocedural factors recorded in the frame of this trial.
Results
The baseline demographic and angiographic data of this subset of
patients were similar to those observed in the entire cohort of the
patients randomized in the RAVEL trial, and the IVUS population
was not the result of a biased selection of patients (Table 1).
Follow-up IVUS was obtained in 80% (95 of 118) of the
eligible patients. The analysis of the 2 groups within the
IVUS population shows that the stent volumes were compa-
rable. At follow-up, there was no difference in the TVV or
PBS volume, suggesting that the eluted drug did not affect the
plaque burden located outside the stent structure (Table 2).
The differences in neointimal hyperplasia and percent of
volume obstruction between the 2 groups were highly signif-
icant, emphasizing the near complete abolition of the prolif-
erative process inside the stent (Figure 2).
The analysis of the proximal and distal edge volumes
showed no significant difference in EEM, lumen, and plaque
volume at the proximal and distal edges (Table 2).
TABLE 1. Comparison of Baseline Demographic and Angiographic Data of the
Population Undergoing IVUS Investigation at Follow-Up With the Entire Cohort of
Randomized Patients
Sirolimus-Coated Stent
(n48)
Uncoated Stent
(n47)
All Randomized
(n238)
Age, y 62.210.7 58.49.7 60.710.4
Men 72.9 85.1 75.6
Diabetes mellitus 14.6 14.9 18.5
Hypercholesterolemia 45.8 52.2 51.5
Hypertension 45.8 53.3 49.2
Previous MI 41.7 27.7 35.7
Previous CABG 2.1 2.1 1.7
Previous PTCA 18.8 8.5 18.1
Current smoker 31.3 40.4 29.8
Unstable angina 58.6 57.4 50.2
Stable angina 32.6 31.9 38.7
Silent ischemia 8.7 10.6 11.1
RVD before procedure, mm 2.590.61 2.660.55 2.620.53
DS after procedure, % 6510 629 6410
MLD before procedure, % 0.900.29 1.010.38 0.950.33
RCA/LAD/CX, % 22.9/54.2/22.9 23.9/52.2/23.9 26.8/49.8/23.4
Values are given as meanSD or percentage.
The difference between demographics and angiographic preprocedure measurements was tested
by Fisher’s exact and unpaired t tests (PNS). MI indicates myocardial infarction; CABG, coronary
artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; RVD, reference vessel
diameter; DS, diameter stenosis; and MLD, minimal luminal diameter.
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Qualitative assessment by IVUS did not reveal any evidence
of intrastent thrombosis or persisting dissection at the stent
edges, but showed a 21% incidence of incomplete apposition in
the sirolimus group compared with a 4% incidence in the
uncoated stent group. Table 3 provides a quantitative evaluation
of the extent of incomplete apposition by the number of
individual segments that were incompletely apposed, as well as
their total length, maximal depth, circumferential extent, and
volume of incomplete apposition. There was no significant
difference between the 2 groups other than the frequency of the
occurrence of this finding (21% versus 4%).
Correlation Between Quantitative Coronary
Angiography and Incomplete Apposition Detected
by IVUS
The binary restenosis rate and the late angiographic loss in
the sirolimus group followed up with IVUS were 0% and
0.060.30 mm, respectively, whereas the restenosis rate
and the late loss in the uncoated stent group were 23.4%
and 0.910.58 mm.
The quantitative coronary angiography analysis of the 48
patients who received a sirolimus-eluting stent showed that
the mean diameter of the stent segment remained unchanged
2.870.46 versus 2.870.49, whereas the mean diameter of
the 47 patients treated with an uncoated stent decreased
significantly from 2.900.42 to 2.170.48 (P0.001). The
mean diameter of the stents in the 10 patients who received a
sirolimus-eluting stent and had incomplete apposition at
follow-up was on average 3.160.57 mm and was signifi-
cantly larger than the mean diameter of the stents of the 38
patients who had their stents well apposed at follow-up
(2.790.43 mm, P0.05). Incomplete apposition was more
likely to occur in larger vessels. Stent diameter, however, was
not used in the multivariate analysis of incomplete apposition.
Clinical Events at 1-Year Follow-Up
In the subset of patients (n95) investigated with IVUS, the
event-free survival rates at 1 year (98% in the sirolimus group
versus 72% in the uncoated stent group, P0.001) are very
similar to the rates observed for the entire cohort of random-
ized patients (94% in the sirolimus group versus 72% in the
uncoated stent group, P0.0001). The 10 patients with
incomplete stent apposition in the sirolimus group were
asymptomatic and event-free at 1 year, whereas 1 of the 2
patients with incomplete apposition in the placebo group
underwent percutaneous target lesion revascularization.
Discussion
The present results confirm the volumetric ultrasound analysis
performed in the First In Man (FIM) trial at 4, 6, and 12
months.1,2 The percent of stent volume obstruction and the
volume of neointimal hyperplasia in the sirolimus group are
comparable to those observed in the FIM trial and are markedly
different from those measured in the control group of the
RAVEL trial. The cumulative frequency curve of the NIH shows
that almost 75% of the stented segments do not exhibit NIH, and
the term naked struts has been coined to describe the IVUS
appearance of the sirolimus-eluting stent struts. It should be
emphasized that the axial resolution of IVUS is in the range of
150 to 200 m and does not permit any assessment of the
reendothelialization. The volume of PBS and the total vessel
volume at follow-up were similar in both groups, suggesting that
no significant plaque shrinking or positive/negative remodeling
occurred as a result of sirolimus elution. This contrasts with what
has been seen with intravascular brachytherapy, where both
positive remodeling of the vessel and plaque progression have
been reported after a 6 to 8-month follow-up.8,9
The quantitative and qualitative assessments in this trial
have demonstrated the absence of an edge effect in drug-
eluting stents when compared with the placebo, the absence
of persisting intimal tears at the stent edges, and the absence
of parietal thrombi or “black holes” inside the stent.
Because of the initial report that there were more cases of late
incomplete apposition detected by IVUS in the sirolimus group,
this observation has created a great deal of interest. It therefore
seemed important to evaluate this phenomenon carefully to
determine whether there were any clinical sequelae to put it in
the proper perspective. Because IVUS assessment of the com-
pleteness of apposition immediately after deployment was not
performed, it is not possible to determine whether these few
cases of incomplete apposition observed at follow-up are the
result of late acquired malapposition or the consequence of an
acute incomplete deployment. Therefore, we have used the
broader term “incomplete apposition.” The completeness of
apposition may be highly dependent on the presence or absence
of intravascular guidance at the time of deployment; in the FIM
trial, performed with IVUS guidance, only 2 cases of late
TABLE 2. IVUS Measurements at 6-Month Follow-Up
Lesion Parameters
Measured
Sirolimus-Eluting Stent (n48) Uncoated Stent (n47)
Proximal Stent Distal Proximal Stent Distal
Total vessel volume 6427 28069 5124 5924* 28075* 4921*
Plaque and NIH 3115 15247 2112 3013* 18353† 2414*
Plaque behind stent NA 15044 NA NA 14643* NA
Stent volume NA 13135 NA NA 13236* NA
Neointimal volume NA 25 NA NA 3728‡ NA
Lumen volume 3316 12934 3014 3015* 9541‡ 2511*
% Stent volume obstruction NA 13 NA NA 2920‡ NA
*Not significant; †P0.05; ‡P0.001.
NA indicates not applicable.
Serruys et al IVUS Findings in the RAVEL Trial 801
acquired malapposition at follow-up were recorded out of 45
patients enrolled in this pilot study. A 17% incidence of acute
incomplete apposition has been reported in a recent series of 62
patients in which bare metal stent deployment, judged optimal
by angiography, was systematically evaluated by IVUS. In the
IVUS-guided trials Stent Treatment Region assessed by Ultra-
sound Tomography (STRUT) and Angiography-directed Versus
IVUS-Directed coronary stent placement trial (AVID), the
incidences of malapposition are 22% and 13%, respectively.20,21
Although the observed frequency of 21% in the sirolimus group
is not very different from those reported with bare stents, it does
not explain the difference seen between the 2 randomized groups
in RAVEL.
Several purely speculative hypotheses may be raised to explain
this general phenomenon. The first is that the antiproliferative action
of the drug may preclude the growth of tissue in the void between
struts and the vessel wall initially created by an incomplete deploy-
ment. The observation that larger vessels were more likely to exhibit
this phenomenon seems to support this hypothesis. Second, the
antimetabolite effect of the drug may induce phenomena such as
necrosis or apoptosis, which may generate a new empty space
between the struts and the vessel wall, which were originally in
close contact. Third, the antimigratory and antiproliferative mecha-
nism of action may prevent myoblasts from colonizing and prolif-
erating in an organized thrombus (for example, in an unstable
patient), which will dissolve at follow-up, creating a new empty
space. A multivariate analysis considering conventional pre-, peri-,
and postprocedural factors recorded in this trial did not identify any
causative factors other than a large minimum luminal diameter after
the procedure, elution of sirolimus, and absence of diabetes as
predictors of incomplete apposition. The more proliferative nature
of the healing process in the diabetic patients, although adequately
inhibited by sirolimus (late loss 0.08 mm in diabetics), may be
sufficient to fill in the gap between the sirolimus-eluting stents and
the vessel wall when stents are initially incompletely deployed. This
may explain why this finding was not present in any of the diabetics
in this study.
Similar observations will undoubtedly be made with stents that
elute drugs other than sirolimus. Serial IVUS observations from the
first human experience with the QP2-eluting polymer stent system
have indicated that mild incomplete stent apposition and persistent
edge tears were observed in 5% and 10%, respectively, of the 20
cases studied in this registry,19 despite the fact that the dose of
taxane analogue used in this registry seems to possess less potent
antimigratory and antiproliferative properties than sirolimus (mean
neointimal area of 1.161.35 mm2 versus of 0.090.26 mm2 in the
present study). The angiographic late loss results reported for
TAXUS I (a Feasibility Study Evaluating Safety of the NIRx
Paclitaxel-Coated Conformer Coronary Stent for the Treatment of
De Novo Coronary Lesions) (0.350.47 mm), the ASian
Paclitaxel-Eluting stent Clinical Trial (ASPECT) study highest dose
(0.290.72 mm) and European EvaLUation of PacliTaxel-Eluting
Stents (ELUTES) highest dose (0.10 0.68 mm), when the range
of standard deviation is factored in, suggest the occurrence of
negative late loss (or late gain) compatible with late malapposition
in some patients, while at the same time suggesting in other patients
substantially more neointimal hyperplasia than observed in the
present study. The clinical significance of these observations in
these trials remains to be determined.
It is of paramount importance to emphasize that in the
sirolimus group, the incomplete apposition detected in some
patients at 6 months did not translate into any subacute or late (1
year) clinical events. Furthermore, late (18-, 24-, and 36-month)
Figure 2. Cumulative distribution curve of in-stent neointimal hyper-
plasia volume at follow-up (A), percent obstruction volume of the stent
at follow-up (B), stent volume at follow-up (C), and in-stent lumen vol-
ume at follow-up (D) for the 48 patients treated with sirolimus-eluting
stent (black lines) and the 47 placebo patients treated with an
uncoated Bx VELOCITY stent (gray line). Although stent volume after
the procedure is similar, the neointimal and percent of obstruction
volume curves are significantly shifted to the left for the sirolimus
group.
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IVUS investigation of cases of malapposition after brachyther-
apy has shown that this phenomenon may disappear at follow-up
(unpublished data, personal communication of J. Ligthart, MSc,
January, 2002). Therefore, the significance of this phenomenon
may be trivial and clinically irrelevant, but longer-term
follow-up will be necessary to answer this question definitively.
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TABLE 3. Characteristics and Quantification of Incomplete Apposition of Stent
Sirolimus-Eluting Stent Uncoated Stent P
Frequency per patient (%) 10/48 (21) 2/47 (4) 0.001
Frequency of incomplete stent apposition as a
function of nominal stent size (patients can
have more than 1 stent)
2.5 mm 1/10 (10) 0/3 (0) NS
3.0 mm 4/27 (15) 3/36 (8) NS
3.5 mm 5/13 (38) 0/9 (0) NS
Number of sites per stent exhibiting
incomplete apposition
1.9 (1–3) 2 (2–2) NS
Localization of incomplete apposition sites
Proximal edge of the stent, % 5/19 (27) 1/4 (25) NS
Middle part of the stent, % 12/19 (63) 3/4 (75) NS
Distal edge of the stent, % 2/19 (10) 0/4 (0) NS
Maximal number of struts separated from
vessel wall on one single cross-section
3.6 (2–5) 4.0 (3–5) NS
Total length on one single or multiple
longitudinal views, mm
6.7 (3.5–13.5) 6.9 (5.3–8.4) NS
Maximal depth, mm 0.75 (0.3–1.2) 0.62 (0.6–0.7) NS
Maximal circumferential extent, arc° 154° (63–270) 131° (104–158) NS
Volume per stent, mm3 20 (3–66) 27 (16–39) NS
Volume per stent volume, % 14 (2–42) 14 (7–20) NS
Values are mean (%) or mean (range).
NS indicates not significant.
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